|
||
|
|
||
| __ | |||
|
|
|||
|
Preimplantation Genetic Screening (PGS) for Aneuploidy Preimplantation Genetic Screening (PGS) for Aneuploidy: screening of high-risk patients of advanced maternal age to reduce recurrent miscarriage and repeated IVF failure Preimplantation genetic screening (PGS) for aneuploidy, or simply, aneuploidy screening, uses the same approach as PGD to identify embryos with abnormal numbers of chromosomes. Many of these embryos are not viable and will either fail to implant, cause miscarriage or rarely result in fetal or congenital abnormalities. Unfortunately, as aneuploid embryos initially develop normally and cannot be distinguished on the basis of their appearance, they are equally likely to be selected for transfer following IVF. There is now growing evidence in patients at high risk that identifying aneuploid embryos by PGS and transferring only embryos with the normal number of the chromosomes analysed can reduce miscarriage rates and reduce the chance of congenital abnormalities associated with aneuploidy. Infertile patients who can benefit from aneuploidy screening include those in which the female partner is of advanced maternal age, couples having recurrent miscarriage (not caused by chromosomal abnormality in the parents) and couples with recurrent IVF failure.
To learn more about PGS and the clinical applications available at Bridge, Click here to go to our specialist website PGD-PGS.com Home
| Best Practice | The Team
| Causes of Infertility
Treatments and Prices | Sharing and Donor Programmes | Medical Services | Update Useful Links | Contact Us | Copyright and Use of Site | Site Map
|
|||
